Vascular Biogenics Ltd (NASDAQ:VBLT) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,285,337 shares, an increase of 34.6% from the February 15th total of 954,769 shares. Based on an average trading volume of 154,364 shares, the days-to-cover ratio is currently 8.3 days. Currently, 15.4% of the shares of the company are short sold.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VBLT. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Vascular Biogenics in the third quarter valued at about $135,000. IFP Advisors Inc boosted its stake in Vascular Biogenics by 339.7% in the fourth quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 15,117 shares during the last quarter. Alps Advisors Inc. purchased a new position in Vascular Biogenics in the fourth quarter valued at about $234,000. ARK Investment Management LLC purchased a new position in Vascular Biogenics in the fourth quarter valued at about $302,000. Finally, Raymond James & Associates lifted its stake in shares of Vascular Biogenics by 71.5% during the 4th quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 23,124 shares in the last quarter. Hedge funds and other institutional investors own 5.61% of the company’s stock.
Vascular Biogenics (NASDAQ:VBLT) opened at $2.50 on Tuesday. The firm has a market cap of $73.57, a PE ratio of -3.16 and a beta of -2.44. Vascular Biogenics has a 52 week low of $2.30 and a 52 week high of $9.05.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/13/short-interest-in-vascular-biogenics-ltd-vblt-expands-by-34-6.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.